Press Releases

Press Releases

Date Title
August 12, 2022
UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
- Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvement in BCVA and CST with favorable safety profile at 12 and 18 weeks - - Near-Term Milestones include
August 12, 2022
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by central subfield
August 11, 2022
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be held on Friday, August 12 at 5:00 a.m. PT/8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or
July 12, 2022
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead
June 29, 2022
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif. , June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from June 14, 2022 , through June 28, 2022 , the Compensation
May 26, 2022
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
SAN FRANCISCO , May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar , current chief financial officer at Assembly Bio, has been appointed
May 25, 2022
UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and
May 10, 2022
UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates
-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION
May 5, 2022
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
Cellular senescence biology in eye disease was a focal point at ARVO opening symposium SOUTH SAN FRANCISCO, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,
April 21, 2022
UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting
SOUTH SAN FRANCISCO, Calif. , April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic
Displaying 11 - 20 of 28